Tetralogic Pharmaceuticals Corp (TLOG) 4.70 $TLOG Nasdaq

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 10:22 PM

Tetralogic Pharmaceuticals Corp (TLOG) 4.70 $TLOG

Nasdaq stocks posting largest volume increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FARO: 44.64 (-0.93), ENZN: 1.70 (+0.20), CDZI: 8.65 (-0.33), BNSO: 1.63 (unch), DTLK: 11.95 (+0.36), NYMX: 1.32 (-0.08), IDSY: 7.02 (+0.13), VLTC: 15.14 (-1.04), TLOG: 4.70 (-0.21), UCTT: 5.66 (+0.14), OBAS: 7.04 (-0.29)

TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B
GlobeNewswire - Tue Apr 21, 7:00AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that research describing birinapant's preclinical activity in a mouse model of chronic human hepatitis B virus (HBV) has been published in the journal Proceedings of the National Academy of Sciences.
TLOG: 4.70 (-0.21)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT

SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), BIOC: 3.15 (+0.02), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), TRIL: 20.67 (-2.53), CZR: 9.68 (-0.24), TLOG: 4.70 (-0.21), BCLI: 4.29 (-0.09), STDY: 10.10 (+0.11), GENE: 4.88 (-0.05), FARO: 44.64 (-0.93), ICON: 27.06 (+0.45), XXII: 1.50 (+0.04), XBIT: 27.55 (+0.18), UEC: 2.12 (+0.29), COOL: 1.40 (-0.21), CALA: 12.93 (-1.06), WPCS: 3.71 (-0.17), VIMC: 13.42 (+1.31)

Merck and TetraLogic Pharma establish clinical study collaboration
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:00AM CDT

MRK: 57.69 (+0.03), TLOG: 4.70 (-0.21)

TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
GlobeNewswire - Mon Apr 20, 7:00AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic's SMAC-mimetic, in combination with KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015.
MRK: 57.69 (+0.03), TLOG: 4.70 (-0.21)

TetraLogic to Present at the 14th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 9:11AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 10:00 a.m. Eastern Time at the Westin Grand Central Hotel in New York. Mr. Buchi will provide an overview of the Company and its corporate activities.
TLOG: 4.70 (-0.21)

TetraLogic beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 3:49PM CST

TLOG: 4.70 (-0.21)

Nasdaq stocks posting largest percentage increases
AP - Thu Feb 05, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
EOPN: 8.59 (unch), HPJ: 4.19 (+0.03), GLUU: 5.55 (+0.44), BPFH: 12.50 (+0.13), TLOG: 4.70 (-0.21), SOFO: 10.00 (+0.05), EGLT: 10.34 (-0.27), BBSI: 42.01 (-1.23), SLAB: 52.98 (+0.08), CONN: 30.39 (+0.40), CBMG: 32.14 (+2.21), ALQA: 4.88 (+0.33), LWAY: 20.32 (-0.52)

TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
GlobeNewswire - Thu Dec 18, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T-cell lymphoma ("CTCL"

.
TLOG: 4.70 (-0.21)

Market Maker Surveillance Report. JRJC, ECSL, TLOG, WLDN, HGSH, EKSO, Losing Stocks With Lowest Price Friction For Tuesday, December 16th 2014
M2 - Wed Dec 17, 2:18AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5122 companies with "abnormal" market making, 2762 companies with positive Friction Factors and 4010 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. China Finance Online Co Ltd (NASDAQ:JRJC), ECARE SOLUTIONS INC (OTC:ECSL), TRANSFORM LOGIC CORP (NASDAQ:TLOG), Willdan Group Inc (NASDAQ:WLDN), China Hgs Real Estate Inc (NASDAQ:HGSH), (OTC:EKSO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
JRJC: 5.63 (+0.09), HGSH: 3.10 (-0.06), TLOG: 4.70 (-0.21), WLDN: 16.11 (-0.03)

TetraLogic Provides Update on Ovarian Cancer Study
GlobeNewswire - Tue Dec 16, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with ovarian cancer. The study is being conducted in patients who have failed up to three rounds of prior chemotherapy. In the study birinapant has been dosed twice weekly, 3 weeks out of 4, or 4 weeks out of 4, in combination with Amgen's TRAIL receptor 2 agonist antibody, conatumumab, dosed every 2 weeks. Patients are scanned for disease status after every 8 weeks (2 cycles).
AMGN: 169.10 (+0.64), TLOG: 4.70 (-0.21)

TetraLogic Pharma perking up
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 9:23AM CST

TLOG: 4.70 (-0.21)

TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 56th Annual American Society of Hematology Annual Meeting
GlobeNewswire - Thu Dec 04, 6:29AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts related to clinical data on birinapant will be presented at the 56 Annual American Society of Hematology meeting to be held in San Francisco from December 6-9, 2014.
TLOG: 4.70 (-0.21)

TetraLogic to Participate in Two Conferences in December
GlobeNewswire - Tue Dec 02, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that company management will participate in the following conferences in New York this month:
TLOG: 4.70 (-0.21)

Andrew L. Pecora of TetraLogic Pharmaceuticals Corporation (TLOG)-NasdaqGM bought Shares of TLOG
M2 - Thu Nov 20, 7:06AM CST
Reported by InsiderCow.com at 2014-11-19 12:36:34 ET
TLOG: 4.70 (-0.21)

TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B
GlobeNewswire - Mon Nov 10, 7:42AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced additional results from preclinical studies that demonstrated the ability of the SMAC-mimetic, birinapant, to clear Hepatitis B Virus (HBV) in mouse models.
TLOG: 4.70 (-0.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...